Primary Hyperparathyroidism by Parathyroid Cancer. Case Report and Review
Article Sidebar
Main Article Content
Abstract
Parathyroid carcinoma (CP) is a malignant disease with an incidence of 0.015 per 100,000 inhabitants per year. It accounts for 1% of primary hyperparathyroidism diagnoses and occurs between the 4th and 5th decade of life, with a similar incidence between men and women. The etiology of CP is uncertain and has been associated with sporadic or family forms.
CP is characterized by high serum calcium and PTH levels and the clinical-surgical challenge is the differential diagnosis with other benign entities such as parathyroid adenoma or
hyperplasia. Although the diagnosis of certainty is achieved by pathological anatomy examination, the clinical suspicion and the use of low complexity methods (ultrasound) by experienced operators allows a correct localization and a patient-speci!c approach to direct the appropriate surgical treatment (block resection), avoiding persistence and recurrences of disease. The clinical case of a male patient admitted for severe hypercalcemia with multiple organ disfunction, the diagnostic approaches, treatment, and
interdisciplinary management, together with review and discussion of the current literature are presented.
Article Details
Derechos de autor: Actualizaciones en Osteología es la revista oficial de la Asociación Argentina de Osteología y Metabolismo Mineral (AAOMM) que posee los derechos de autor de todo el material publicado en dicha revista.
References
Del Bosque-Méndez J, Soto-Becerril O, Hernández-Abarca E, et al. Cáncer de Paratiroides. Rev Hosp Jua Mex 2018; 85(3):168-72
Wei C, Harari A. Parathyroid Carcinoma: Update and guidelines for management. Curr Treat Options Oncol 2012 Mar; 13(1):11-23
Stanka Kirigin Bilos L, Pavlovic D, Kellar F. Parathyroid Carcinoma: a diagnostic and treatment challenge. Association for Endocrine Oncology and Metabolism. September 15th 2016.
Valenzuela M.J, Encalada C, Gerasch T, Brenet R, Acuña S. Parathyroid cancer and hypercalcemia difficult to manage. A diagnostic challenge. Rev Chil End Diab 2019;12(4): 205-7
Lumachi F, Basso S, Basso U. Parathyroid Cancer: Etiology, Clinical Presentation and Treatment. Anticancer Research 2006;26:4803-8.
Bhattacharyya A, Buckler HM, New JP. Hungry Bone Syndrome-Revisited. Current Medicine. J R Coll Physicians Edinb 2002;32:83-6.
Angeli A, Dovio A. The hungry bone: expected and unexpected. Ann Ital Med Int 2004;19:4-6.
Ghilardi G, De Pasquale L. Hungry bone syndrome after parathyroidectomy for primary hyperthyroidism. Surgery Current Research 2014; 4:2.
Witteveen JE, Van Thiel S, Romijn JA, Hamdy N. Hungry Bone Syndrome: still a challenge in the post – operative management of primary hyperparathyroidism: a systematic review of the literature. European Journal of Endocrinology 2013;168: R45-R53.
Crucelegue S, Rosa Diez G, Serra D, Ortiz M, Diehl M. Síndrome de hueso hambriento asociado al hiperparatiroidismo secundario en la enfermedad renal crónica. Actual Osteol 2014;10(1):11-9.
Machado M, Wilheim S. Parathyroid Cancer: A review. Cancers 2019; 11:1676. doi 10.3390.
Collaud C y col. Uso de la 18F-colina PET TC en hiperparatiroidismo primario persistente/recurrente. Actual Osteol 2019:15(1):11-9.
Carlson D. Parathyroid Pathology: Hyperparathyroidism and Parathyroid Tumors. Arch Pathol Lab Med 2010;134 (11):1639-44.
Seethala R. R, Virji MA, Ogilvie JB. Pathology of the parathyroid glands. In: Barnes L (ed). Surgical Pathology of the Head and Neck. Vol III. New York: Informa Health Care. 2009. Pp.1429-72.
Okamoto T Iihara M, Obara T, Tsukada T. Parathyroid carcinoma: etiology, diagnosis, and treatment. World J Surgery 2009;33(11):2343-54.
Rosai J. Parathyroid glands. In: Rosai J. Rosai and Ackerman's Surgical Pathology. 9th ed. New York: Mosby. 2004. pp.595-619.
Campbell LK, Thomas JR, Lamps LW, Brunce MD, Smoller BR, Folpe A. Protein Gene Product 9.5 (PGP 9.5) Is Not a Specific Marker of Neural and Nerve Sheath Tumors: An Immunohistochemical Study of 95 Mesenchymal Neoplasms. Modern Pathology 2003; 16: 963-9.
Rumack CM, Charboneau JW, Levine D. Diagnóstico en ecografía. 4-a ed. Madrid: Marbán; 2014. Capítulo 19, pp. 671-89.
Mohebati A, Shaha AR,.DeLellis RA. Tumors of the Parathyroid Gland. Localizing studies. Armed Forces Institute of Pathology. 1993. Atlas of Tumor Pathology. 3rd series, fascicle 6.
Hirokawa M, Suzuki A, Higuchi M, et al. Histological alterations following fine‐needle aspiration for parathyroid adenoma: Incidence and diagnostic problems. Pathology International 2021;71:400-5
Ferraro V, Sgaramella L, Di Meo G, et al. Current concepts in parathyroid carcinoma: a single centre experience. BMC Endocrine Disorders 2019;19(Suppl 1):46.
Turan P, Johnson S, Bliss RD, Lennard TW, Aspinall SR. Parafibromin, Galectin-3, PGP9.5, Ki67, and Cyclin D1: Using an Immunohistochemical Panel to Aid in the Diagnosis of Parathyroid Cancer. World J Surg 2014; 38:2845-54.
Drnovsek M, Ercolano M, Rubin Z y col. Carcinoma y adenoma atípico de paratiroides: Datos nacionales. Rev Argent Endocrinol Metab 2020;57:12-9.
Stock JL, Weintraub BD, Rosen SW, Aurbach GC, Spiegel AM, Marx SJ. Human Chorionic Gonadotropin Subunit Measurement in Primary Hyperparathyroidism. J Clinical Endocrinol Metab 1982; 54: 57.
Limberg J, Stefanova D, Ullmann T, et al. The Use and Benefit of Adjuvant radiotherapy in Parathyroid Carcinoma: A National Cancer Database Analysis. Ann Surg Oncol 2021;28:502-11.
Apaydin T, Yavuz D. Seven cases of parathyroid carcinoma and review of the literature. Teaching case presentations. Hellenic Endocrine Society 2020.
Le Collen L, Barraud S, Braconnier A, et al. A large extended family with hyperparathyroidism-jaw tumor syndrome due to deletion of the third exon of CDC73: clinical and molecular features. Endocrine 2021;73:693-701.
Panya C, Uzilov AV, Bellizi J, et al. Genomic Profiling Reveals Mutational Landscape in Parathyroid Carcinomas. JCI Insight 2017;2:e92061 1-14.